Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003930 · ClinicalTrials.gov registry record · Phase 1
Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer
A Phase 1 study, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 84
- Enrollment target
NCT00003930 is a Phase 1 study that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 84 participants.
The verdict
NCT00003930, a Phase 1 study, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 84 participants
- Enrollment target
Study Summary
RATIONALE: Radiation therapy uses x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy and surgery may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of radiation therapy plus combination chemotherapy in treating patients who have stage II or stage III bladder cancer that can be removed by surgery.
Interventions
- DRUG cisplatin
- DRUG paclitaxel
- PROCEDURE conventional surgery
- RADIATION radiation therapy
- DRUG gemcitabine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 1999-09 |
| Est. Completion | 2013-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003930
The ClinicalTrials.gov registry entry for NCT00003930 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT00003930 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003930 about?
NCT00003930 is a clinical study titled "Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer". RATIONALE: Radiation therapy uses x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy and surgery may kill more tumor cells. PURPOSE: Phase I/II trial to study the ef...
What is the current status of trial NCT00003930?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 84 participants. The study started on 1999-09. Estimated completion is 2013-11.
What interventions are being tested in trial NCT00003930?
The interventions under investigation include: cisplatin (DRUG), paclitaxel (DRUG), conventional surgery (PROCEDURE), radiation therapy (RADIATION), gemcitabine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00003930?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.